Phaeochromocytoma

📋 Key Information Summary

📋

Phaeochromocytoma is a catecholamine-secreting tumour of the adrenal medulla; paragangliomas are extra-adrenal catecholamine-secreting tumours arising from sympathetic or parasympathetic paraganglia.
Approximately 10% are bilateral, 10% extra-adrenal, 10% malignant (based on metastatic disease), and 10% hereditary — though recent genetic data suggest hereditary cases may account for up to 30–40%.
The classic triad is episodic headache, sweating, and palpitations — but the clinical presentation is heterogeneous; suspicion should be high in paroxysmal or resistant hypertension.
Plasma free metanephrines are the recommended first-line biochemical test (sensitivity >96%, specificity ~89%); 24-hour urinary fractionated metanephrines and catecholamines are acceptable alternatives.
CT abdomen/pelvis with contrast is the preferred first-line anatomical imaging; functional imaging with ¹²³I-MIBG or ⁶⁸Ga-DOTATATE PET/CT is used for metastatic disease, extra-adrenal tumours, or hereditary syndromes.
Alpha-adrenergic blockade must be commenced at least 10–14 days pre-operatively to prevent intra-operative hypertensive crisis; phenoxybenzamine (non-selective) is the traditional agent; doxazosin (selective α₁) is an alternative.
Beta-blockade is added only AFTER adequate alpha-blockade to avoid unopposed alpha stimulation and paradoxical hypertensive crisis.
Pre-operative preparation includes volume expansion (high-salt diet, IV saline), and blood pressure/heart rate targets should be achieved before surgery.
Laparoscopic adrenalectomy is the standard surgical approach; open surgery is reserved for large (>6 cm) or invasive tumours.
All patients should undergo genetic testing (minimum panel: RET, VHL, SDHB, SDHD, SDHC, SDHA, MAX, TMEM127, NF1) as hereditary syndromes are present in up to 40% of cases.
Malignant phaeochromocytoma/paraganglioma (defined by metastatic disease) has a 5-year survival of approximately 50%; cyclophosphamide–vincristine–dacarbazine (CVD) and ¹³¹I-MIBG therapy are systemic options.
Long-term follow-up is mandatory regardless of apparent benign pathology, as recurrence/metastasis can occur decades later — annual biochemical and clinical surveillance is recommended for at least 10 years.
In Australia, cases should be managed by a multidisciplinary endocrine tumour team including endocrinology, endocrine surgery, anaesthetics, genetics, nuclear medicine, and oncology.

🎧 Audio Brief

Clinical guidelines for adrenaline producing tumors

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Introduction & Australian Epidemiology

Phaeochromocytoma is a catecholamine-secreting neuroendocrine tumour arising from chromaffin cells of the adrenal medulla. When catecholamine-secreting tumours arise from extra-adrenal chromaffin tissue, they are termed paragangliomas. Together, phaeochromocytomas and paragangliomas (PPGL) are considered in the same clinical framework.

The incidence is approximately 2–8 per million population per year, with a peak incidence in the fourth to fifth decades of life. PPGLs are found in approximately 0.1–0.6% of patients with hypertension. In Australia, this equates to roughly 50–100 new diagnoses per year, though improved biochemical testing and imaging have increased detection rates.

The traditional “rule of 10s” (10% bilateral, 10% extra-adrenal, 10% malignant, 10% hereditary) remains a useful heuristic but is an oversimplification. Current data indicate hereditary germline mutations are present in approximately 30–40% of cases, with the proportion even higher in paediatric and bilateral presentations. The term “malignant” is now defined by the presence of metastatic disease (to sites where chromaffin tissue is not normally present) rather than histological features, as no single pathological criterion reliably predicts behaviour.

Undiagnosed phaeochromocytoma carries significant morbidity and mortality due to catecholamine-driven hypertensive crises, arrhythmias, cardiomyopathy, stroke, and multi-organ failure. Prompt biochemical diagnosis, appropriate pre-operative preparation, and surgical resection offer cure in the majority of benign cases.

Pathophysiology & Genetics

Pathophysiology

Phaeochromocytomas arise from chromaffin cells of the adrenal medulla, which are derived from the neural crest. These cells normally synthesise, store, and secrete catecholamines (primarily noradrenaline and adrenaline) under physiological regulation. In phaeochromocytoma, autonomous catecholamine overproduction occurs independent of normal regulatory feedback, leading to sustained or paroxysmal elevation of circulating catecholamines.

The haemodynamic effects of catecholamine excess include:

Alpha-1 receptor activation → peripheral vasoconstriction → hypertension
Beta-1 receptor activation → increased heart rate, contractility, and myocardial oxygen demand
Beta-2 receptor activation → bronchodilation, glycogenolysis, gluconeogenesis
Metabolic effects: hyperglycaemia, lipolysis, increased basal metabolic rate

Noradrenaline-secreting tumours (predominantly paragangliomas) tend to cause sustained hypertension, whereas adrenaline-secreting tumours (typically adrenal phaeochromocytomas, especially those associated with MEN2) are more commonly associated with paroxysmal hypertension and tachyarrhythmias. Tumour location determines the predominant catecholamine: adrenal phaeochromocytomas contain phenylethanolamine N-methyltransferase (PNMT) and can produce adrenaline, while extra-adrenal paragangliomas generally lack PNMT and secrete noradrenaline.

Genetic Syndromes

At least 20 susceptibility genes have been identified. Genetic testing should be offered to ALL patients with PPGL, as hereditary syndromes are present in 30–40% of cases and have implications for screening, surveillance, and family counselling.

Syndrome / Gene	Inheritance	PPGL Features	Other Manifestations
VHL (von Hippel–Lindau)	AD	10–20% develop PPGL; often bilateral; noradrenergic phenotype	Renal cell carcinoma, retinal/cerebellar haemangioblastomas, pancreatic NETs
RET (MEN2A/2B)	AD	50% in MEN2A, 50% in MEN2B; usually bilateral; adrenergic phenotype	Medullary thyroid carcinoma, primary hyperparathyroidism (2A), mucosal neuromas (2B)
NF1 (Neurofibromatosis 1)	AD	1–5% develop PPGL; predominantly adrenal	Neurofibromas, café-au-lait spots, optic gliomas, skeletal abnormalities
SDHB	AD	High risk of malignancy (30–50%); often extra-adrenal/paraganglioma	Renal cell carcinoma (type 2), pituitary adenoma
SDHD	AD (paternal imprinting)	Often multiple head/neck paragangliomas; low malignancy risk	Head and neck parasympathetic paragangliomas
SDHC/SDHA/SDHAF2	AD	Lower penetrance; head/neck paragangliomas predominance	Variable
TMEM127	AD	Usually benign; predominantly adrenal	Associated with renal cell carcinoma
MAX	AD	Often bilateral; moderate malignancy risk	Variable
FH	AD	Aggressive; high malignancy risk	Hereditary leiomyomatosis, renal cell carcinoma

AD = autosomal dominant; NET = neuroendocrine tumour.

⚠️

SDHB mutations carry the highest malignancy risk (30–50%). All patients with SDHB mutations require lifelong surveillance, and first-degree relatives should be offered predictive genetic testing.

In Australia, genetic testing can be performed through public hospital genetics services or private laboratories (e.g., Sonic Genetics, Douglass Hanly Moir). A minimum panel should include RET, VHL, SDHB, SDHD, SDHC, SDHA, MAX, TMEM127, and NF1. Broader next-generation sequencing (NGS) panels encompassing additional genes (FH, MDH2, SLC25A11, DLST, GOT2, IDH3B) are increasingly available.

Clinical Features

The Classic Triad

The classic presentation of phaeochromocytoma comprises three symptoms occurring episodically:

Headache — typically severe, throbbing, and sudden in onset (present in ~90% of symptomatic episodes)
Diaphoresis — profuse sweating, often drenching (present in ~60–70%)
Palpitations — forceful, rapid heartbeat (present in ~50–70%)

When all three are present simultaneously, the positive predictive value for phaeochromocytoma is high. However, the complete triad occurs in only approximately 40% of patients at presentation.

Broader Symptom Profile

Symptoms are often paroxysmal, lasting minutes to hours, and may be triggered by physical exertion, abdominal palpation, micturition (bladder paraganglioma), certain drugs, anaesthesia, or surgery. Between episodes, patients may be asymptomatic.

Symptom / Sign	Approximate Frequency
Headache	60–90%
Diaphoresis	55–75%
Palpitations / tachycardia	50–70%
Hypertension (sustained or paroxysmal)	80–90%
Anxiety / panic / sense of doom	40–50%
Tremor	30–40%
Nausea / vomiting	25–40%
Flushing	10–30%
Chest / abdominal pain	15–30%
Weight loss	15–30%
Pallor	10–20%
Constipation	10–20%
Hyperglycaemia	10–30%

Hypertensive Crises

🚨

Phaeochromocytoma crisis is a life-threatening emergency characterised by severe hypertension (often SBP >200 mmHg) accompanied by signs of end-organ dysfunction: encephalopathy, myocardial ischaemia/infarction, cardiomyopathy (acute Takotsubo-like or catecholamine-induced), arrhythmias, pulmonary oedema, or multi-organ failure. Mortality in untreated crisis is high. Immediate management requires IV phentolamine (1–5 mg bolus, repeatable) or sodium nitroprusside, followed by careful beta-blockade once alpha-blockade is established.

Catecholamine crises may be the initial presentation and can be precipitated by:

Anaesthesia induction or surgical manipulation
Bladder instrumentation or micturition (bladder paraganglioma)
Certain medications: metoclopramide, opioids (morphine), beta-blockers (unopposed alpha), tricyclic antidepressants, contrast dye
Childbirth
Vigorous abdominal palpation

Phaeochromocytoma-Induced Cardiomyopathy

Catecholamine excess can cause reversible cardiomyopathy resembling Takotsubo (stress) cardiomyopathy, dilated cardiomyopathy, or catecholamine-induced myocarditis. Recovery typically occurs after tumour resection and alpha-blockade.

Investigations

Biochemical Testing

Biochemical confirmation is essential before any imaging. The Endocrine Society Clinical Practice Guideline (2014, reaffirmed 2023) recommends measurement of plasma free metanephrines or urinary fractionated metanephrines as the first-line test.

First-line

Plasma free metanephrines (metanephrine + normetanephrine)

Sensitivity >96%, specificity ~89%. Collect supine, after 20–30 min rest, via indwelling cannula. Avoid caffeine, acetaminophen, and tricyclic antidepressants for 48 hours prior (interfere with HPLC-MS/MS). Available at major Australian pathology (Sullivan Nicolaides, Douglass Hanly Moir, SA Pathology). MBS item available.

Alternative

24-hour urinary fractionated metanephrines and catecholamines

Sensitivity ~90%, specificity ~95%. Useful when plasma testing is equivocal or unavailable. Avoid certain foods (bananas, vanilla, caffeine) and medications for 48 hours. Widely available through Australian pathology services.

Adjunct

Plasma free catecholamines (noradrenaline, adrenaline, dopamine)

Lower sensitivity and specificity than metanephrines; may be used as adjunct. Blood must be collected supine with strict pre-analytical handling (ice transport, rapid centrifugation).

Specialist

Clonidine suppression test

For equivocal biochemical results. Measure plasma normetanephrine before and 3 hours after clonidine 300 mcg PO. Failure to suppress plasma normetanephrine supports phaeochromocytoma. Specialist centres only.

⚠️

Interfering medications: Tricyclic antidepressants, phenoxybenzamine, and labetalol can elevate measured metanephrines. Ideally, withdraw interfering medications for 2 weeks before testing. If this is not feasible, interpret results with caution and consider clonidine suppression testing.

Interpretation of Results

Elevation of plasma free normetanephrine to >3× the upper limit of normal has a positive predictive value >95%. Mild elevations (1–3× ULN) require confirmatory testing (repeat measurement, 24-hour urine, or clonidine suppression). Catecholamine levels <ULN effectively exclude phaeochromocytoma.

Anatomical Imaging

First-line

CT abdomen and pelvis with contrast

Sensitivity ~95% for adrenal tumours >1 cm. Characteristically bright on non-contrast CT (high vascularity), avidly enhancing with contrast, with rapid washout. Available at all Australian centres. MBS item available.

Alternative

MRI abdomen (with gadolinium)

Preferred in paediatric patients, pregnant women, and for head/neck paragangliomas. Characteristic “light-bulb” bright signal on T2-weighted imaging. Avoids ionising radiation. Available at all major centres.

Functional Imaging

Functional imaging is indicated when anatomical imaging is negative, for metastatic staging, extra-adrenal disease localisation, or hereditary syndromes with multifocal disease.

Specialist

¹²³I-MIBG (meta-iodobenzylguanidine) scintigraphy

Sensitivity ~85–90% for sporadic phaeochromocytoma; lower for metastatic disease and SDHB-related tumours. Available at major Australian centres (Royal North Shore, St Vincent’s Melbourne, Peter MacCallum, Royal Adelaide). Requires referral to nuclear medicine. MBS item available.

Specialist

⁶⁸Ga-DOTATATE PET/CT

Superior sensitivity to MIBG for metastatic disease, hereditary syndromes (especially SDHB), and head/neck paragangliomas. Increasingly available in Australia (Peter MacCallum, Royal Brisbane, Royal North Shore, Fiona Stanley). Often the preferred functional imaging modality in current practice.

Specialist

¹⁸F-FDG PET/CT

Useful for aggressive/metastatic phaeochromocytoma, especially SDHB-related. Higher sensitivity than MIBG for poorly differentiated tumours. Widely available.

Other Investigations

ECG: May show left ventricular hypertrophy, ST changes, T-wave inversions, prolonged QTc, or arrhythmias
Echocardiography: Assess for catecholamine cardiomyopathy, especially in patients with heart failure symptoms or troponin elevation
Troponin: Elevated in catecholamine-induced myocardial injury
Chromogranin A: Non-specific but may be elevated; useful as a tumour marker for surveillance post-operatively

Risk Stratification & Malignancy Assessment

Malignancy in phaeochromocytoma/paraganglioma is defined solely by the presence of metastases at sites where chromaffin tissue is not normally found (e.g., bone, liver, lung, lymph nodes). No single histological feature reliably predicts malignant behaviour. The PASS (Pheochromocytoma of the Adrenal Scaled Score) and GAPP (Grading System for Adrenal Pheochromocytoma and Paraganglioma) scoring systems provide histological risk estimation but are not diagnostic of malignancy.

Low Risk

Benign Sporadic Adrenal Phaeochromocytoma

Solitary, <5 cm, low PASS score, no SDHB mutation, noradrenergic or adrenergic phenotype. Complete surgical resection is curative.

Setting: Adrenalectomy with standard surveillance

Moderate Risk

Hereditary / Bilateral / Extra-adrenal

VHL, RET, MAX, TMEM127 mutations; bilateral disease; extra-adrenal paraganglioma; large tumours (>5 cm); high PASS score (>6). Increased risk of recurrence or multifocal disease.

Setting: Surgical resection + enhanced surveillance + genetic counselling

High Risk

Metastatic / Malignant Disease

SDHB mutation, extra-adrenal sympathetic paraganglioma >5 cm, multifocal metastases, high mitotic index. 5-year survival ~50%.

Setting: Multidisciplinary tumour board — systemic therapy, radionuclide therapy, palliative surgery

ℹ️

Genetic testing changes risk: SDHB mutations confer 30–50% lifetime risk of metastatic disease. Even small, apparently benign SDHB-related tumours require aggressive long-term surveillance.

Management

Pre-Operative Preparation — Alpha-Blockade

Pre-operative alpha-adrenergic blockade is mandatory and should be initiated at least 10–14 days (optimally 2–4 weeks) before scheduled surgery. The goal is to control hypertension, expand contracted intravascular volume, and prevent intra-operative catecholamine crisis during tumour manipulation.

💊

Phenoxybenzamine

Dibenyline® · Non-selective irreversible alpha-blocker

Adult dose 10 mg PO BD initially; titrate by 10–20 mg every 2–3 days. Usual maintenance 20–40 mg BD–TDS (max 120 mg/day)

Paediatric dose 0.2 mg/kg/dose PO BD; titrate gradually

Duration 10–14 days minimum pre-operatively; continue until surgery

Key side effects Postural hypotension, reflex tachycardia, nasal congestion, miosis, GI upset

PBS status PBS Authority Required

💊

Doxazosin

Cardura® · Selective α₁-blocker (alternative)

Adult dose 1 mg PO daily; titrate by doubling every 3–7 days. Usual dose 4–16 mg daily

Advantages Shorter-acting (less post-op hypotension); fewer side effects than phenoxybenzamine. Increasingly preferred at many Australian centres.

PBS status ✔ PBS General Benefit

⚠️

Targets for adequate alpha-blockade: Sitting BP <130/80 mmHg, standing SBP >90 mmHg (with mild orthostatic drop acceptable). Heart rate 60–70 sitting, 70–80 standing. Presence of mild nasal congestion confirms adequate alpha-blockade.

Beta-Blockade

🚨

NEVER commence a beta-blocker before adequate alpha-blockade. Unopposed alpha-stimulation causes severe vasoconstriction and paradoxical hypertensive crisis, which may be fatal.

Beta-blockers are added AFTER 2–3 days of alpha-blockade if persistent tachycardia (>100 bpm) persists.

💊

Propranolol

Inderal® · Non-selective beta-blocker

Adult dose 10–20 mg PO TDS; titrate to HR target

PBS status ✔ PBS General Benefit

💊

Atenolol

Tenormin® · Selective β₁-blocker (alternative)

Adult dose 25–50 mg PO daily

PBS status ✔ PBS General Benefit

Volume Expansion

Alpha-blockade causes vasodilation and relative volume contraction. Patients should be encouraged to consume a high-sodium diet (6–8 g salt/day) and liberal oral fluids. IV 0.9% sodium chloride (1–2 L over 12–24 hours) may be administered in the days before surgery, particularly if orthostatic symptoms are significant.

Additional Pre-Operative Agents

💊

Metyrosine (α-methyltyrosine)

Catecholamine synthesis inhibitor

Adult dose 250 mg PO QID; increase to 1 g QID if required

Role Not PBS-listed in Australia. Reserved for refractory cases or when alpha-blockade alone is insufficient. Inhibits tyrosine hydroxylase, reducing catecholamine synthesis by 35–80%.

PBS status ✘ Not PBS

💊

Nicardipine

Calcium channel blocker

Adult dose 20–30 mg PO TDS as adjunct for BP control

Role May be added if BP remains elevated despite alpha-blockade. Useful in patients with asthma who cannot tolerate beta-blockers.

PBS status PBS Authority Required (IV)

Surgical Management

Surgical resection is the definitive treatment for phaeochromocytoma. Laparoscopic adrenalectomy (anterior or lateral transperitoneal, or retroperitoneal) is the standard of care for tumours <6 cm without evidence of local invasion. Open adrenalectomy is indicated for tumours >6 cm, suspected malignancy/invasion, or for bilateral cortical-sparing procedures.

1

Pre-Operative Anaesthetic Assessment

Dedicated endocrine anaesthetist with phaeochromocytoma experience. Confirm alpha-blockade adequacy. Large-bore IV access ×2. Arterial line. Continuous invasive BP monitoring.

2

Intra-Operative Management

IV phentolamine (1–5 mg boluses), sodium nitroprusside, or nitroglycerin for hypertensive surges during tumour manipulation. IV esmolol or labetalol for tachyarrhythmias. Massive fluid resuscitation often required after tumour vein ligation (catecholamine withdrawal → vasodilation → hypotension). Vasopressors (noradrenaline infusion) frequently needed.

3

Post-Operative Care

HDU/ICU for at least 24 hours. Monitor for hypotension, hypoglycaemia (loss of catecholamine-driven glycogenolysis), and rebound hypotension. Check plasma metanephrines at 2–6 weeks post-op to confirm biochemical cure.

4

Cortical-Sparing (Partial) Adrenalectomy

Considered for bilateral phaeochromocytoma (MEN2, VHL, NF1) to preserve adrenal cortical function and avoid lifelong steroid replacement. Risk of local recurrence ~10–15%. Requires expert surgical team.

Management of Malignant / Metastatic Disease

For patients with metastatic phaeochromocytoma or paraganglioma, the following systemic and locoregional therapies may be considered:

¹³¹I-MIBG therapy: High-specific-activity MIBG (Azedra®) has demonstrated efficacy in metastatic disease. Available at select Australian centres via special access schemes.
¹⁷⁷Lu-DOTATATE PRRT: Peptide receptor radionuclide therapy for somatostatin receptor-positive tumours (e.g., Lutathera®). PBS-listed for gastroenteropancreatic NETs; available off-label for PPGL at specialist centres.
CVD chemotherapy: Cyclophosphamide 750 mg/m² + Vincristine 1.4 mg/m² + Dacarbazine 600 mg/m² days 1–2 (every 21 days). Response rate ~50% (mostly partial).
Sunitinib: Tyrosine kinase inhibitor showing activity in metastatic PPGL (37.5 mg daily). Not PBS-listed for this indication.
Temozolomide: Particularly active in SDHB-mutated tumours (response rate ~30–40%). 200 mg/m² days 1–5 every 28 days.
Palliative surgery: Cytoreductive surgery for symptom control when feasible.
External beam radiotherapy: For bone metastases or local symptom control.

Long-Term Surveillance

All patients require lifelong annual biochemical surveillance (plasma free metanephrines) regardless of tumour histology. Minimum recommended follow-up is 10 years, but indefinite surveillance is preferred, as recurrence and metastasis have been reported >20 years post-resection.

Time Post-Op	Biochemistry	Imaging	Notes
2–6 weeks	Plasma metanephrines	Nil unless elevated	Confirm biochemical cure
Annually (years 1–5)	Plasma metanephrines ± chromogranin A	CT/MRI if hereditary or high-risk	Lifelong for SDHB; annual
Annually (years 5–10+)	Plasma metanephrines	Imaging if symptomatic or rising markers	Continue indefinitely for hereditary

Special Populations

🤰 Pregnancy

Phenoxybenzamine:

Category C. Can be used in pregnancy when benefits outweigh risks. Preferred alpha-blocker.

Labetalol:

Category C. Combined alpha/beta blocker; may be useful when beta-blockade also needed.

Diagnosis is challenging as catecholamine levels rise physiologically in pregnancy. MRI (no radiation) is preferred imaging. Surgery in second trimester is safest if diagnosed early; caesarean section with concurrent adrenalectomy may be considered in the third trimester. Vaginal delivery carries high risk of catecholamine crisis.

👶 Paediatrics

Phaeochromocytoma in children has a higher rate of hereditary syndromes (up to 70%), bilateral disease, and extra-adrenal paraganglioma. All children require comprehensive genetic testing. MRI is preferred over CT to minimise radiation exposure. Paediatric doses of phenoxybenzamine: 0.2 mg/kg/dose BD, titrated. Cortical-sparing surgery should be considered for bilateral disease to avoid adrenal insufficiency.

👴 Elderly

Higher risk of postural hypotension from alpha-blockade; titrate more slowly. Comorbid cardiovascular disease may complicate management. Pre-operative cardiac assessment (including echocardiography) is essential. Surgical fitness must be carefully evaluated; inoperable patients may benefit from alpha-blockade alone for symptom control.

🫘 Renal Impairment

Phenoxybenzamine:

No specific dose adjustment, but start low and titrate cautiously due to drug accumulation.

Monitor fluid balance closely; volume overload is a risk with aggressive IV saline in CKD. Renal impairment may also cause elevated plasma metanephrines, complicating biochemical interpretation.

🫁 Hepatic Impairment

Phenoxybenzamine is hepatically metabolised; use with caution in significant hepatic disease. Consider dose reduction. Liver metastases from malignant phaeochromocytoma may cause additional hepatic dysfunction. Metyrosine is contraindicated in severe hepatic impairment.

🛡️ Immunocompromised

No specific interactions with standard immunosuppressive regimens. However, patients receiving chemotherapy for malignant phaeochromocytoma require monitoring for cytopenias and infection risk. Cortical-sparing surgery in immunocompromised patients requires careful adrenal reserve assessment.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiological context

While phaeochromocytoma is rare across all populations, Aboriginal and Torres Strait Islander peoples experience higher rates of hypertension, cardiovascular disease, and diabetes — conditions that may mask or complicate the diagnosis of catecholamine-secreting tumours. Clinicians should maintain a high index of suspicion for secondary causes of hypertension in Indigenous Australians with resistant or young-onset hypertension.

Remote & rural access

Specialist endocrine services, functional imaging (MIBG, DOTATATE PET), and genetic testing are concentrated in major metropolitan centres. Aboriginal and Torres Strait Islander peoples in remote and very remote communities may face significant barriers to timely diagnosis, pre-operative preparation, and post-operative surveillance. Telehealth endocrinology consultations, RFDS-supported evacuation pathways, and outreach specialist clinics are essential for equitable care.

Genetic testing & counselling

Genetic testing is critical for identifying hereditary syndromes and enabling cascade screening of family members. Culturally appropriate genetic counselling services should be offered, with consideration of family structures, kinship systems, and communication preferences. Genetic services should be accessible via telehealth with Indigenous health worker support.

Surgical & peri-operative care

Patients in remote areas will need transfer to a tertiary centre for adrenalectomy. Pre-operative alpha-blockade must be initiated and monitored prior to transfer where possible. Post-operative follow-up may require coordination with local Aboriginal Medical Services (AMS) or Remote Area Health Corps practitioners.

Long-term surveillance

Annual biochemical surveillance (plasma metanephrines) must be accessible to Indigenous patients post-resection. This requires reliable pathology collection in remote areas, appropriate sample handling (cold chain for plasma metanephrines), and follow-up pathways with endocrinology. Integration with chronic disease management programmes (e.g., MBS 715 health assessments) may facilitate ongoing monitoring.

Cultural safety

Care should be delivered with cultural safety principles: involve Aboriginal Health Workers and Liaison Officers, provide information in plain language and culturally appropriate formats, respect gender preferences for clinical interactions, and support patient travel/accommodation through state/territory Patient Assisted Travel Schemes (PATS).

📚 References

1. Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–1942.
2. Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476–1490.
3. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019;381(6):552–565.
4. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23(34):8812–8818.
5. Crona J, Taïeb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev. 2017;38(6):489–515.
6. Australian Institute of Health and Welfare (AIHW). Cardiovascular disease, diabetes and chronic kidney disease — Australian facts: Aboriginal and Torres Strait Islander people. Canberra: AIHW; 2015.
7. Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775–783.
8. Hamidi O, Young WF Jr, Iñiguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017;102(9):3296–3305.
9. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008;155(3):408–417.
10. Bausch B, Schiavi F, Ni Y, et al. Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention. JAMA Oncol. 2017;3(9):1204–1212.
11. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
12. Nölting S, Bechmann N, Taïeb DA, et al. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev. 2022;43(2):199–239.